If you have fully recovered from COVID-19, you may be able to help patients currently fighting the infection by donating your plasma.
FDA’s Technology Modernization Action Plan
The plan describes important near-term actions that FDA is taking to modernize use of technology—computer hardware, software, data, and analytics—to advance FDA’s public health mission.
Fostering Drug Competition
Increasing the availability of generic drugs helps to create competition in the marketplace, helping make treatment more affordable and increasing access to healthcare for more patients.
Combating the Opioid Crisis
FDA takes actions to combat prescription opioid abuse.
Sundial Herbal Products is Recalling Products Attached Because these Products were Misbranded. The Products are Currently Unapproved Drugs, Recall is Required by the Order
Food & Beverages
Lupin Pharmaceuticals, Inc. Issues Voluntarily Nationwide Recall of Metformin Hydrochloride Extended-Release Tablets, 500mg and 1000mg Due to the Detection of N-Nitrosodimethylamine (NDMA) Impurity
Food & Beverages
Partnering with the European Union and Global Regulators on COVID-19
The FDA and the European Commission (EC) and its European Medicines Agency (EMA) are collaborating on many fronts as part of our COVID-19 response.
FDA Maintains the Pace of Meeting Its Goals on Applications for Medical Products During the Pandemic
FDA has maintained the same pace of meeting its goals on review of applications for medical products during the pandemic that it has maintained in recent years.
Rare Disease Therapy Development and Access Remain Top FDA Priorities During COVID-19
FDA’s work to advance treatments for rare diseases and helping ensure continuity of care for people with rare diseases remain top priorities during COVID-19.
Select Updates for Peripheral Vascular Atherectomy Devices - Premarket Notification [510(k)] Submissions
Cancer Clinical Trial Eligibility Criteria: Patients with Organ Dysfunction or Prior or Concurrent Malignancies
Cancer Clinical Trial Eligibility Criteria: Minimum Age Considerations for Inclusion of Pediatric Patients